Unlocking the potential of retinoic acid in anticancer therapy

T. Schenk, S. Stengel, Arthur Z Zelent

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

All-trans-retinoic acid (ATRA) is a physiologically active metabolite of vitamin A. Its antitumour activities have been extensively studied in a variety of model systems and clinical trials; however, to date the only malignancy responsive to ATRA treatment is acute promyelocytic leukaemia (APL) where it induces complete remission in the majority of cases when administered in combination with light chemotherapy and/or arsenic trioxide. After decades of studies, the efficacy of ATRA to treat other acute myeloid leukaemia (AML) subtypes and solid tumours remains poor. Recent studies directed to improve ATRA responsiveness in non-APL AML seem to indicate that the lack of effective ATRA response in these tumours may be primarily due to aberrant epigenetics, which negatively affect ATRA-regulated gene expression and its antileukaemic activity. Epigenetic reprogramming could potentially restore therapeutic effects of ATRA in all AML subtypes. This review discusses the current progresses in the understanding how ATRA can be utilised in the therapy of non-APL AML and other cancers.

Original languageEnglish (US)
Pages (from-to)2039-2045
Number of pages7
JournalBritish Journal of Cancer
Volume111
Issue number11
DOIs
StatePublished - Nov 25 2014

Fingerprint

Tretinoin
Acute Myeloid Leukemia
Therapeutics
Epigenomics
Neoplasms
Acute Promyelocytic Leukemia
Therapeutic Uses
Vitamin A
Clinical Trials
Gene Expression
Light
Drug Therapy

Keywords

  • combination therapy
  • epi-drugs
  • KDM1A
  • LSD1
  • RAR
  • retinoic acid receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Unlocking the potential of retinoic acid in anticancer therapy. / Schenk, T.; Stengel, S.; Zelent, Arthur Z.

In: British Journal of Cancer, Vol. 111, No. 11, 25.11.2014, p. 2039-2045.

Research output: Contribution to journalArticle

Schenk, T. ; Stengel, S. ; Zelent, Arthur Z. / Unlocking the potential of retinoic acid in anticancer therapy. In: British Journal of Cancer. 2014 ; Vol. 111, No. 11. pp. 2039-2045.
@article{1d38ea754d614317997b8007c62a78b5,
title = "Unlocking the potential of retinoic acid in anticancer therapy",
abstract = "All-trans-retinoic acid (ATRA) is a physiologically active metabolite of vitamin A. Its antitumour activities have been extensively studied in a variety of model systems and clinical trials; however, to date the only malignancy responsive to ATRA treatment is acute promyelocytic leukaemia (APL) where it induces complete remission in the majority of cases when administered in combination with light chemotherapy and/or arsenic trioxide. After decades of studies, the efficacy of ATRA to treat other acute myeloid leukaemia (AML) subtypes and solid tumours remains poor. Recent studies directed to improve ATRA responsiveness in non-APL AML seem to indicate that the lack of effective ATRA response in these tumours may be primarily due to aberrant epigenetics, which negatively affect ATRA-regulated gene expression and its antileukaemic activity. Epigenetic reprogramming could potentially restore therapeutic effects of ATRA in all AML subtypes. This review discusses the current progresses in the understanding how ATRA can be utilised in the therapy of non-APL AML and other cancers.",
keywords = "combination therapy, epi-drugs, KDM1A, LSD1, RAR, retinoic acid receptor",
author = "T. Schenk and S. Stengel and Zelent, {Arthur Z}",
year = "2014",
month = "11",
day = "25",
doi = "10.1038/bjc.2014.412",
language = "English (US)",
volume = "111",
pages = "2039--2045",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Unlocking the potential of retinoic acid in anticancer therapy

AU - Schenk, T.

AU - Stengel, S.

AU - Zelent, Arthur Z

PY - 2014/11/25

Y1 - 2014/11/25

N2 - All-trans-retinoic acid (ATRA) is a physiologically active metabolite of vitamin A. Its antitumour activities have been extensively studied in a variety of model systems and clinical trials; however, to date the only malignancy responsive to ATRA treatment is acute promyelocytic leukaemia (APL) where it induces complete remission in the majority of cases when administered in combination with light chemotherapy and/or arsenic trioxide. After decades of studies, the efficacy of ATRA to treat other acute myeloid leukaemia (AML) subtypes and solid tumours remains poor. Recent studies directed to improve ATRA responsiveness in non-APL AML seem to indicate that the lack of effective ATRA response in these tumours may be primarily due to aberrant epigenetics, which negatively affect ATRA-regulated gene expression and its antileukaemic activity. Epigenetic reprogramming could potentially restore therapeutic effects of ATRA in all AML subtypes. This review discusses the current progresses in the understanding how ATRA can be utilised in the therapy of non-APL AML and other cancers.

AB - All-trans-retinoic acid (ATRA) is a physiologically active metabolite of vitamin A. Its antitumour activities have been extensively studied in a variety of model systems and clinical trials; however, to date the only malignancy responsive to ATRA treatment is acute promyelocytic leukaemia (APL) where it induces complete remission in the majority of cases when administered in combination with light chemotherapy and/or arsenic trioxide. After decades of studies, the efficacy of ATRA to treat other acute myeloid leukaemia (AML) subtypes and solid tumours remains poor. Recent studies directed to improve ATRA responsiveness in non-APL AML seem to indicate that the lack of effective ATRA response in these tumours may be primarily due to aberrant epigenetics, which negatively affect ATRA-regulated gene expression and its antileukaemic activity. Epigenetic reprogramming could potentially restore therapeutic effects of ATRA in all AML subtypes. This review discusses the current progresses in the understanding how ATRA can be utilised in the therapy of non-APL AML and other cancers.

KW - combination therapy

KW - epi-drugs

KW - KDM1A

KW - LSD1

KW - RAR

KW - retinoic acid receptor

UR - http://www.scopus.com/inward/record.url?scp=84927175614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927175614&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.412

DO - 10.1038/bjc.2014.412

M3 - Article

C2 - 25412233

AN - SCOPUS:84927175614

VL - 111

SP - 2039

EP - 2045

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 11

ER -